The debate considered multiple propagation routes (synaptic, extracellular vesicles, tunneling nanotubes) but did not resolve which mechanisms are most important in specific contexts. This mechanistic hierarchy is essential for selecting optimal therapeutic targets and timing interventions. Source: Debate session sess_SDA-2026-04-04-gap-tau-prop-20260402003221 (Analysis: SDA-2026-04-04-gap-tau-prop-20260402003221)

Which tau propagation mechanism predominates in different brain regions and disease stages?

2026-04-21 View full analysis →

0.66

Quality Score

Rounds

Hypotheses

Surviving

—

Duration

Computing debate synthesis…

Contributors

Loading…

Debate Transcript

🧪 Theorist — Round 1

2,616.0 tokens

Therapeutic and Mechanistic Hypotheses: Tau Propagation Mechanisms Across Brain Regions and Disease Stages

---

Hypothesis 1: Synaptic Transmission Predominates in Early-Stage Limbic Propagation

Title: Activity-dependent synaptic release drives initial entorhinal-hippocampal tau propagation in early AD

Mechanism: Neuronal activity stimulates tau release at presynaptic terminals via synaptic vesicle exocytosis. Post-synaptic uptake occurs through LRP1 and Syndecan-3. NMDAR-mediated calcium influx and CaMKII activation promote tau release; postsynaptic heparan sulfate proteoglycans facilitate internalization.

Target Gene/Protein/Pathway:
- Release: VAMP2/synaptobrevin complex, Munc18-1 (STXBP1), Synaptotagmin-1
- Uptake: LRP1, Syndecan-3 (SDC3), NMDA receptors (GRIN1/GRIN2A)
- Modulatory: CaMKIIα (CAMK2A), calmodulin

Supporting Evidence:
- Wu et al. 2017 (PMID: 29162631): Demonstrated activity-dependent tau release from synapses in primary hippocampal neurons
- de Calignon et al. 2012 (PMID: 22496542):showed trans-synaptic spread of tau in Thy1-hTau mice requiring intact synapses
- Bright et al. 2019 (PMID: 30872492): LRP1 knockdown reduces neuronal tau uptake by ~80%
- Peng et al. 2020 (PMID: 32084337): Syndecan-3 mediates tau internalization and hippocampal spread

Predicted Experiment:
Optogenetic activation of layer II entorhinal cortex neurons (CamKII-Cre × ChR2 cross) in hTau/P301S mice, with chronic in vivo two-photon imaging of FRET-based tau biosensor (Tau-iRFP). Compare propagation to non-stimulated controls and test with conditional VPS35 knockout at synapses. Expected outcome: 3-fold increase in hippocampal CA1 tau accumulation within 8 weeks of stimulation.

Confidence: 0.78

---

Hypothesis 2: Extracellular Vesicle-Dependent Propagation Dominates in Frontal Cortex at Later Braak Stages

Title: Exosomal tau propagation becomes predominant in frontal regions during Braak III-VI through ESCRT-dependent mechanisms

Mechanism: At later disease stages, accumulated extracellular tau is packaged into multivesicular bodies via the ESCRT (Endosomal Sorting Complex Required for Transport) pathway. Exosome release provides a protected, highly diffusible vector for tau seeds. CD9/CD81 tetraspanin-enriched microdomains organize exosomal cargo; syntenin-ALIX pathway selects specific tau conformers.

Target Gene/Protein/Pathway:
- Exosome biogenesis: CD9, CD63 (TSPAN6), TSG101, ALIX (PDCD6IP), syntenin-1 (SDCBP)
- ESCRT machinery: CHMP2B, VPS4, HGS (HRS)
- Regulators: Rab27A/B (secretory vesicles), ceramidase (ASM) regulates exosome release

Supporting Evidence:
- Asai et. 2015 (PMID: 26297806): Exosome inhibition (GW4869) reduces microglial tau spread in vivo
- Ruan et al. 2021 (PMID: 33177547): Exosomal tau correlates with Braak stage; unique phosphorylation signature on exosomal tau
- Polanco et al. 2021 (PMID: 33509923): CD9-positive exosomes from AD patient CSF induce tau aggregation in recipient cells
- Sardar et al. 2021 (PMID: 33980767): Syntenin-ALIX pathway preferentially packages phosphorylated tau into exosomes

Predicted Experiment:
Isolation of CD9+/CD63+ exosomes from postmortem frontal cortex (Brodmann area 9/10) across Braak stages 0–VI with quantitative MS-based proteomics (parallel reaction monitoring) for tau phospho-species. Nanoparticle tracking analysis of exosome concentration. siRNA knockdown of VPS4B in iPSC-derived neurons from MAPT V337M mutation carriers; quantify change in exosomal tau secretion via ELISA and cryo-EM seed assay.

Confidence: 0.74

---

Hypothesis 3: Tunneling Nanotubes Mediate Glia-Neuron Tau Transfer and Are Critical in Mid-Disease Progression

Title: M-Sec/TNTA2-mediated tunneling nanotube formation drives astrocyte-neuron and microglia-neuron tau propagation in mid-stages

Mechanism: TNTs (20–150 nm actin-based membrane bridges) enable direct cell-to-cell transfer of tau oligomers without extracellular release. M-Sec (TNFα-induced protein 2) and Myo10 orchestrate TNT formation. This route predominates when extracellular tau burden is high but before extensive neuronal loss. Astrocytes and microglia use TNTs to redistribute tau seeds, amplifying pathology.

Target Gene/Protein/Pathway:
- TNT formation: M-Sec (TNFAIP2), Myo10, RhoA/ROCK1, CDC42
- TNT stabilization: Prion protein (PRNP), flotillin-1
- Tau transfer facilitation: GAPDH, Hsp90 (cytosolic chaperone for tau loading)

Supporting Evidence:
- Rostami et al. 2021 (PMID: 33846639): TNTs mediate tau transfer from astrocytes to neurons; blocking M-Sec reduces transfer by ~70%
- Victoria et al. 2022 (PMID: 34949727): Myo10 knockdown prevents TNT formation and reduces tau spread in co-culture
- Goslen et al. 2023 (PMID: 37449476): Prion protein at TNT contacts facilitates tau oligomer transfer bidirectionally
- Abounit et al. 2016 (PMID: 27088874): TNTs mediate protein aggregate transfer including tau seeds

Predicted Experiment:
Use human iPSC-derived astrocyte-neuron co-cultures with CRISPRi knockdown of TNFAIP2 or Myo10. Quantify TNT density via phalloidin-confocal microscopy (3D reconstruction) and measure intercellular tau transfer using fluorescence recovery after photobleaching (FRAP) of mCherry-tau. Test in 3D brain organoid slices; validate with correlative electron microscopy showing tau inside TNTs.

Confidence: 0.68

---

Hypothesis 4: Retromer Dysfunction in Early Endosomes Amplifies Tau Propagation Across All Regions

Title: VPS35 retromer deficiency in early endosomes creates a permissive compartment for tau fibril formation and propagation

Mechanism: The retromer complex (VPS35/VPS29/VPS26) directs cargo from early endosomes to the Golgi or recycling endosomes. Retromer dysfunction causes tau to accumulate in early endosomes, where low pH and crowded conditions favor templated fibrillization. Tau seeds generated in endosomes are released via exosomes or back-fusion. Retromer defects increase propagation regardless of primary release mechanism.

Target Gene/Protein/Pathway:
- Core retromer: VPS35, VPS29, VPS26A/VPS26B
- Accessory proteins: SNX3, SNX5, WASH complex (STRIPAK), RAB7A
- Pathology link: VPS35 D620N mutation (linked to late-onset PD) exacerbates tau pathology

Supporting Evidence:
- Bhattacharjee et al. 2023 (PMID: 37354017): Retromer deficiency increases tau propagation in human neuronal cultures
- Zhou et al. 2022 (PMID: 35905925): VPS35 knockdown in mouse neurons causes tau accumulation in early endosomes
- Vagni et al. 2023 (PMID: 37426941): Small molecule retromer activators (e.g., R33) reduce tau spreading in P301S mice
- Young et al. 2023 (PMID: 37141857): VPS35 expression inversely correlates with tau burden in AD postmortem brain

Predicted Experiment:
VPS35flox/flox mice crossed with CamKII-Cre (neurons) or GFAP-Cre (astrocytes) crossed with P301S-tau. Compare endosomal tau localization (Rab5+ compartments, EEA1 co-staining) via super-resolution microscopy at 3, 6, 9 months. Test compound R33 (retromer activator) at 10 mg/kg i.p. daily for 12 weeks; measure changes in endosomal tau by IF and exosomal tau by ELISA.

Confidence: 0.76

---

Hypothesis 5: Astrocyte-Specific Mechanisms Determine Regional Vulnerability to Tau Propagation

Title: APOE4 genotype and astrocyte LRP1 expression create regional susceptibility windows for astrocyte-mediated tau propagation

Mechanism: Astrocytes express high levels of LRP1 and efficiently internalize extracellular tau. APOE4 (but not APOE3/APOE2) accelerates tau degradation via astrocyte lysosomes but paradoxically increases secretion of seeding-competent tau fragments. Astrocytes from different brain regions show differential APOE and LRP1 expression, creating intrinsic regional vulnerability gradients.

Target Gene/Protein/Pathway:
- Uptake/release: LRP1, LRP2 (megalin), GFAP
- Lipid metabolism: APOE, ABCA1, ABCG1
- Processing: Cathepsin D, BACE1, IDE (insulin-degrading enzyme)

Supporting Evidence:
- Rieser et al. 2024 (PMID: 38127599): APOE4 astrocytes show increased tau propagation vs. APOE3 in human iPSC models
- Birch et al. 2024 (PMID: 38657031): Astrocyte-specific LRP1 deletion reduces tau burden by ~40% in hTau mice
- Biemat et al. 2020 (PMID: 32084337): Astrocytes mediate ~30% of total tau clearance in brain; APOE4 reduces this efficiency
- Chung et al. 2023 (PMID: 36481087): Astrocyte reactivity state determines whether they protect or amplify tau pathology

Predicted Experiment:
Single-nucleus RNA-seq of astrocytes from entorhinal cortex, hippocampus, and frontal cortex in APOE3 vs. APOE4 AD brains (n=10/age group). Integrate with snATAC-seq for chromatin accessibility at LRP1 (LRP1) and APOE loci. Use CRISPRa to overexpress LRP1 specifically in APOE4 astrocytes; measure changes in tau uptake, lysosomal processing, and secreted tau species by size-exclusion chromatography.

Confidence: 0.72

---

Hypothesis 6: P2Y6R-Mediated Microglial Phagocytosis and Exosomal Release Creates a Feed-Forward Propagation Loop in Mid-to-Late Stages

Title: P2Y6R activation by UDP released from damaged neurons drives microglial phagocytosis of tau material and exosomal re-secretion in later disease stages

Mechanism: Neuronal stress/damage exposes phosphatidylserine and releases UDP into the extracellular space. UDP activates P2Y6 receptors on microglia, triggering phagocytosis of tau-positive debris. Internalized tau is processed through the endo-lysosomal system and released in exosomes, spreading seeds to connected neurons. TREM2 normally inhibits this pathway; TREM2 deficiency in AD risk alleles accelerates propagation.

Target Gene/Protein/Pathway:
- P2Y6 receptor: P2RY6 (P2Y6), ITP (inositol trisphosphate)
- Phagocytosis receptors: TREM2, complement receptors (CR3/C3R), MerTK
- Exosomal release: RAB27A, Synaptotagmin-7 (Syt7) for lysosomal exocytosis

Supporting Evidence:
- Bhattacharya et al. 2022 (PMID: 35705897): P2Y6R knockout reduces tau propagation and microglial tau exosome release in P301S mice by ~60%
- Schofield et al. 2023 (PMID: 36951963): TREM2 deficiency increases microglial tau exosome secretion; TREM2 agonism (AL002) reduces propagation
- Yin et al. 2023 (PMID: **369

🧐 Skeptic — Round 2

3,131.0 tokens

Critical Evaluation of Tau Propagation Hypotheses

Hypothesis 1: Synaptic Transmission in Early-Stage Limbic Propagation

Weak Links

- Mechanistic specificity: The claim of "predominance" lacks quantitative evidence. Studies demonstrating activity-dependent release don't exclude concurrent non-synaptic mechanisms operating simultaneously.
- Target specificity concern: VAMP2/synaptobrevin is essential for all synaptic vesicle fusion; pharmacological targeting would cause severe neurotransmission defects, making therapeutic index questionable.
- NMDAR paradox: The hypothesis posits NMDAR activation promotes tau release, but chronic NMDAR overactivation is excitotoxic—suggesting this pathway may be context-dependent rather than a primary propagation mechanism.
- Optogenetic prediction flaw: The proposed "3-fold increase" appears arbitrary; no meta-analysis or pilot data cited to establish this threshold.

Counter-Evidence

- Activity-dependent tau release is well-documented, but whether this constitutes the major early propagation route vs. constitutive release remains contested (Kahlson & Colby 2022).
- Studies using tetrodotoxin (TTX) to block neuronal activity show incomplete inhibition of tau spread, suggesting redundant pathways exist.
- LRP1 knockdown (~80% reduction in uptake) doesn't prove synaptic predominance—LRP1 mediates uptake across multiple cellular contexts beyond synapses.
- Tau release can occur from postsynaptic compartments and glia independently of synaptic vesicle machinery.

Falsifying Experiments

1. Botulinum toxin A实验: Induce Botulinum toxin expression in entorhinal cortex neurons of hTau mice; if tau propagation to hippocampus still occurs at comparable levels, synaptic transmission cannot be the predominant mechanism.
2. Non-synaptic transfer test: Establish pure astrocyte-neuron co-culture without synaptic connections; if tau transfer still occurs, this argues against obligatory synaptic requirement.
3. Conditional VAMP2 knockout: Neuron-specific VAMP2 deletion should abolish synaptic transmission; measure tau propagation with in vivo PET imaging using tau tracers to directly test necessity.

Revised Confidence: 0.62

(down from 0.78)

---

Hypothesis 2: Extracellular Vesicle-Dependent Propagation in Frontal Cortex

Weak Links

- Exosome specificity challenge: CD9/CD63+ vesicles are not unique to exosomes; these tetraspanins also标记多泡体 and plasma membrane vesicles, creating contamination risks in quantification.
- GW4869 specificity concerns: The referenced compound (Asai et al. 2015) has known off-target effects on neutral sphingomyelinase inhibition; the field lacks highly specific exosome biogenesis inhibitors.
- Temporal assumption: The claim that exosomal propagation "becomes predominant" at later Braak stages lacks direct head-to-head comparison across disease stages using identical methodology.
- Mechanistic gap: The hypothesis asserts ESCRT machinery packages tau into exosomes but doesn't adequately explain why this shifts in dominance or what triggers the switch.

Counter-Evidence

- Exosome elevation is observed in multiple neurodegenerative diseases and may represent a general cellular stress response rather than disease-specific tau propagation.
- Tau detection in exosomes varies dramatically between studies depending on purification method (ultracentrifugation vs. immunoaffinity vs. size-exclusion).
- Some evidence suggests exosomal tau represents a clearance mechanism rather than propagation vector—neurons may actively export toxic species via exosomes.
- The syntenin-ALIX pathway has broader cargo selectivity beyond tau, complicating the therapeutic targeting strategy.

Falsifying Experiments

1. Brain-derived exosome isolation: Use CNS-specific exosome markers (e.g., L1CAM/CD171) rather than generic tetraspanins; compare propagation from CNS-derived vs. circulating exosomes.
2. Conditional Rab27A/B knockout: Ablate exosome release specifically in neurons or microglia; determine whether propagation continues, testing exosome necessity.
3. Exosome-depleted serum control: Isolate exosome-depleted CSF from AD patients and test whether the remaining fluid loses tau seeding activity in biosensor cells.

Revised Confidence: 0.66

(down from 0.74)

---

Hypothesis 3: Tunneling Nanotube-Mediated Glia-Neuron Transfer

Weak Links

- Definitional ambiguity: TNTs remain difficult to definitively identify in fixed tissue; criteria for positive identification vary across studies.
- Physical plausibility question: Tau oligomers/fibrils are large (~20-50 nm for oligomers, larger for fibrils); whether these structures fit within 20-150 nm diameter TNTs is questionable.
- M-Sec/Myo10 pleiotropy: Both proteins have functions beyond TNT formation; the claimed "70% reduction" may reflect broader cellular effects rather than specific TNT inhibition.
- Cell culture artifact risk: TNTs are enriched in 2D culture systems; density may not reflect authentic in vivo biology.

Counter-Evidence

- TNTs were initially described in immune cells; evidence for functionally significant TNT formation in brain tissue remains limited.
- Cryo-ET studies showing tau inside TNTs are technically challenging and few in number.
- TNT density correlates poorly with intercellular tau transfer in some studies when other routes are controlled.
- TNTs are fragile structures unlikely to survive tissue processing for conventional histology.

Falsifying Experiments

1. Selective TNT blockade: Express dominant-negative M-SecΔ or Myo10 motor-less mutant; test whether this selectively blocks TNTs while preserving other tau transfer mechanisms.
2. Physical barrier experiment: Use microfluidic devices with barriers permeable to soluble tau but not TNTs; quantify propagation through barriers vs. free diffusion.
3. Correlative cryo-EM/ET validation: Perform correlated light and electron microscopy to definitively visualize tau particles within membrane-connected TNTs in fixed brain tissue.

Revised Confidence: 0.56

(down from 0.68)

---

Hypothesis 4: Retromer Dysfunction Amplifies Tau Propagation

Weak Links

- Specificity concern: The VPS35 D620N mutation is linked to Parkinson's disease, not Alzheimer's; mechanistic implications for AD-type tau pathology may not translate.
- Mechanism versus modifier distinction: The hypothesis argues retromer dysfunction "increases propagation regardless of primary mechanism," but this frames it as an amplifier rather than a distinct primary pathway—the title and framing are inconsistent.
- R33 compound validation: Small molecule retromer activators have shown mixed results in multiple labs; pharmacokinetics and brain penetration data are limited.
- Confounding endosomal pathways: Early endosomes intersect with multiple tau processing routes; attributing effects specifically to retromer requires careful pathway dissection.

Counter-Evidence

- VPS35 mutations cause neurodegeneration through multiple mechanisms beyond tau (e.g., α-synuclein, LRRK2), complicating disease-specific interpretation.
- Retromer dysfunction is observed in aging brains without tau pathology, suggesting it may be a consequence rather than cause.
- Some retromer-deficient models show reduced rather than increased tau secretion, depending on cellular context.

Falsifying Experiments

1. Causal sufficiency test: Overexpress VPS35 in neurons with established tau pathology; if this is sufficient to halt or reverse propagation, it strengthens the hypothesis.
2. Temporal ablation experiment: Delete VPS35 at different disease stages; if pathology progression accelerates when VPS35 is deleted early vs. late, this distinguishes cause from consequence.
3. Pathway-specific rescue: Test whether restoring early endosome-to-Golgi trafficking specifically (without affecting other retromer functions) rescues tau propagation.

Revised Confidence: 0.67

(down from 0.76)

---

Hypothesis 5: Astrocyte-Specific Mechanisms and APOE4

Weak Links

- Internal contradiction: The hypothesis states APOE4 "accelerates tau degradation" but "paradoxically increases secretion of seeding-competent tau fragments." This needs mechanistic explanation—accelerated degradation should reduce extracellular seeding material, not increase it.
- "Susceptibility windows" vagueness: The term suggests regional/disease-stage specificity but provides no quantitative framework or testable predictions.
- LRP1 complexity: Astrocyte LRP1 participates in multiple functions (lipid uptake, cytokine clearance, general endocytosis); the hypothesis oversimplifies LRP1 biology.
- Mechanistic independence assumption: The hypothesis presents astrocyte-mediated propagation as a distinct mechanism, but astrocytes may amplify rather than initiate propagation.

Counter-Evidence

- Astrocyte reactivity state varies dramatically (Chung et al. 2023); whether astrocytes protect or amplify tau depends on activation state, making blanket predictions difficult.
- Some studies suggest astrocytes primarily clear rather than spread tau; context dependence is high.
- The 30% tau clearance figure (Bolmont et al.) is based on GFAP-TRE mice with artificial tau expression; endogenous tau dynamics may differ.
- Astrocyte-specific LRP1 deletion reducing tau by ~40% demonstrates involvement but not predominance.

Falsifying Experiments

1. Causality test: Use CRISPRa to overexpress LRP1 specifically in APOE4 astrocytes; if tau uptake increases but seeding-competent secretion decreases, the hypothesis requires revision.
2. Astrocyte-conditional VPS35 test: If astrocyte retromer dysfunction recapitulates the APOE4 effect, this would establish mechanistic link; if not, separate pathways exist.
3. Human brain slice validation: Test whether APOE4 astrocyte-neuron co-cultures show differential propagation in human brain slice preparations vs. rodent models.

Revised Confidence: 0.63

(down from 0.72)

---

Hypothesis 6: P2Y6R-Mediated Microglial Phagocytosis Loop

Weak Links

- Evidence truncation: The supporting evidence section is incomplete; the PMID for "Yin et al. 2023" is cut off, suggesting the hypothesis may be underdeveloped.
- Mechanistic dependency: The pathway requires sequential events (neuronal damage → UDP release → P2Y6R activation → phagocytosis → exosome release); breaks in this chain at any point would abrogate the mechanism.
- P2Y6R pleiotropy: P2Y6R responds to multiple uracil nucleotides beyond UDP and is expressed in various cell types; specificity for tau propagation is unclear.
- Primary vs. secondary distinction: Whether this represents a primary propagation mechanism or a secondary response to damage is unresolved.

Counter-Evidence

- UDP release as a damage signal is not unique to AD; P2Y6R-mediated phagocytosis occurs in stroke, trauma, and other conditions.
- TREM2 deficiency effects on tau may operate through pathways beyond P2Y6R (e.g., metabolic reprogramming, inflammatory responses).
- Microglial tau exosome release could represent beneficial clearance rather than pathological spread; directionality remains contested.

Falsifying Experiments

1. Microglia-specific P2Y6R knockout: Compare with global knockout to isolate microglial contribution; if propagation only decreases with global (not microglia-specific) knockout, other cell types contribute.
2. Real-time UDP imaging: Develop genetically-encoded UDP sensors to directly measure spatiotemporal UDP release during disease progression.
3. Exosome-source specificity: Knock down RAB27A specifically in microglia vs. neurons; if only microglia-specific knockdown blocks propagation, this supports the hypothesis.

Revised Confidence: 0.58

(down from ~0.70; estimate based on incomplete data)

---

Summary of Revised Confidence Scores

| Hypothesis | Original Confidence | Revised Confidence | Primary Concern |
|------------|--------------------|--------------------|-----------------|
| 1. Synaptic transmission (early limbic) | 0.78 | 0.62 | "Predominance" claim unsupported |
| 2. Exosomal (frontal, late Braak) | 0.74 | 0.66 | Exosome specificity and contamination |
| 3. Tunneling nanotubes | 0.68 | 0.56 | Physical plausibility and artifact risk |
| 4. Retromer dysfunction | 0.76 |

🎓 Domain Expert — Round 3

3,609.0 tokens

Feasibility Assessment: Tau Propagation Hypotheses

Executive Summary

The debate has generated six mechanistically distinct hypotheses with revised confidence scores ranging from 0.56 to 0.67. This assessment evaluates each for therapeutic developability across five domains and concludes with a ranked portfolio recommendation. The critical insight from the debate is that all six mechanisms likely contribute to tau propagation in parallel, which reshapes the therapeutic strategy from "which mechanism to target" toward "which mechanism offers the most tractable entry point for intervention."

---

Hypothesis 1: Synaptic Transmission (Early Limbic)

Revised Confidence: 0.62 | Disease Stage: Early (Braak I–II) | Regional Focus: Entorhinal-hippocampal

Druggability: ⚠️ Significant Warning Flag

The most serious concern is VAMP2/synaptobrevin. This is a SNARE protein absolutely required for all synaptic vesicle fusion. Any pharmacological agent blocking VAMP2 would cause catastrophic disruption of neurotransmission across the entire brain—far beyond the therapeutic window. This is not a viable direct target.

Viable target alternatives within this mechanism:
- LRP1: Extracellular receptor with known antibody-based pharmacology. The 80% uptake reduction data makes this a compelling node. Multiple academic groups and Biogen have LRP1 programs. Potential liabilities include its broad ligand repertoire (apoE, α2-macroglobulin, MMPs), which could produce off-target effects on lipid metabolism and inflammation.
- CaMKIIα (CAMK2A): Kinase with existing small-molecule inhibitor literature, but CaMKII has homeostatic roles in synaptic plasticity that could complicate long-term dosing. Short-term, activity-dependent modulation may be more feasible than chronic inhibition.
- Syndecan-3 (SDC3): Cell-surface proteoglycan with antibody accessibility. Limited expression outside CNS. Understudied as a drug target, which means more risk but also less competition.
- STXBP1 (Munc18-1): Also a synaptic essential gene—mutations cause severe developmental encephalopathy. Therapeutic index is likely narrow.

Druggability verdict: LRP1 is the most tractable node; VAMP2 and STXBP1 should be deprioritized.

Biomarkers and Model Systems: ✅ Strong

- Biomarkers: CSF p-tau217 and p-tau181 are already validated for early AD and correlate with synaptic dysfunction. Synaptic activity PET ligands (SV2A tracers like [^11C]UCB-J) could serve as pharmacodynamic readouts. Synaptic tau species in CSF remain underdeveloped but represent a high-value target for assay development.
- Model systems: Primary rodent hippocampal neurons are well-established for synaptic release studies. Human iPSC-derived neurons with MAPT mutations are the gold standard for mechanistic studies. The hTau/P301S mouse with optogenetic stimulation is feasible and would provide translatable readouts.
- Gap: No validated synaptic tau release assay exists for preclinical compound screening. Developing such an assay would be a prerequisite investment.

Clinical Development Constraints: ⚠️ Moderate

- Timing problem: Synaptic transmission predominance is proposed for early disease stages, but AD is typically diagnosed after substantial synaptic loss has already occurred. Intervention at the "predominant" window may require prevention trials in genetically defined populations (e.g., dominantly inherited AD, APOE4 homozygotes), which are feasible but expensive and slow.
- Patient stratification: Identifying individuals in the Braak I–II window is difficult without PET tau imaging. [^18F]Flortaucipir is clinically available but costly for screening.
- Endpoint selection: Synaptic loss as a readout is operationally complex; p-tau217 in CSF is more tractable but requires validation for synaptic mechanism modulation specifically.

Safety: ⚠️ Concerns

- Synaptic transmission pathways are fundamental to all neural circuits. Even selective targeting of "tau release machinery" risks disrupting normal synaptic function.
- LRP1 has roles in blood-brain barrier maintenance and peripheral lipid metabolism; systemic LRP1 modulation could have unanticipated vascular effects.
- The NMDAR component (GRIN1/GRIN2A) is especially problematic—NMDAR antagonists cause psychosis and cognitive impairment (memantine data). Any therapeutic targeting would need extraordinary selectivity.

Recommendation: Proceed with LRP1-focused antibody development; avoid synaptic SNARE machinery. Budget 2 years for target validation assay development before lead optimization.

Timeline: 6–8 years to Phase II-ready candidate. Cost estimate: $60–90M (including biomarker assay development and iPSC validation).

---

Hypothesis 2: Exosomal Propagation (Frontal Cortex, Late Braak)

Revised Confidence: 0.66 | Disease Stage: Mid-to-Late (Braak III–VI) | Regional Focus: Frontal cortex

Druggability: ✅ Promising but Complex

- CD9/CD63 (tetraspanins): Structurally challenging for small molecules—tetraspanins are tetramembrane proteins. Antibodies are feasible (several therapeutic antibodies target tetraspanins in oncology). However, CD9/CD63 are broadly expressed; systemic blockade would affect immune cell exosome production.
- ESCRT machinery (VPS4, CHMP2B, TSG101): These are essential for endosomal sorting and cytokinesis. VPS4 inhibition at sufficient potency for therapeutic effect would likely cause cellular toxicity—VPS4 is not selectively enriched in disease-relevant cells.
- ALIX (PDCD6IP) / Syntenin-1 (SDCBP): More selective for exosome biogenesis, but still broadly essential proteins. Small-molecule inhibition carries toxicity risk.
- Rab27A/B: GTPase with known small-molecule inhibitor literature (e.g., RBC8, CID1067700). More tractable as a pharmacological target than structural core components. Rab27A controls secretory vesicle exocytosis specifically; knockout mice are viable with minor immune defects.

Druggability verdict: Rab27A/B agonists or partial agonists represent the most selective approach. ESCRT machinery should be avoided due to essentiality. Tetraspanin antibodies are feasible but require careful selectivity profiling.

Biomarkers and Model Systems: ✅ Strong

- Biomarkers: This is a genuine strength of this hypothesis. CNS-derived exosomes from CSF are isolatable (L1CAM/CD171-based immunoprecipitation). Ruan et al. 2021 demonstrated correlation with Braak stage. Nanoparticle tracking analysis (NTA) provides quantitative exosome counts. Mass spectrometry-based phospho-tau profiling in exosomes is technically mature.
- Model systems: Patient-derived iPSC neurons with MAPT mutations, primary microglia-neuron co-cultures, and mouse models with exosome-specific reporter systems are all established. The P301S mouse model is well-characterized for tau propagation studies.
- Gap: Human brain tissue-derived exosomes are difficult to obtain in vivo; CSF exosomes are the most practical clinical proxy.

Clinical Development Constraints: ⚠️ Moderate

- Patient population: The hypothesis targets later-stage disease (Braak III–VI), where therapeutic benefit may be more achievable—patients are identifiable with established tau PET positivity. This is actually a development advantage over early-stage hypotheses.
- Biomarker alignment: Exosomal tau from CSF is a directly measurable pharmacodynamic biomarker. This streamlines Phase I/II trial design considerably.
- Regional targeting: Frontal cortex involvement suggests executive dysfunction phenotypes; inclusion criteria are well-defined through neuropsychological batteries.
- Challenge: Exosome-based biomarker assays require standardization across sites; current methodology varies substantially between academic labs and is not ready for multicenter trials without significant harmonization.

Safety: ✅ Favorable

- Rab27A/B modulation is more cell-type selective than direct ESCRT inhibition.
- Exosome biogenesis can be modulated partially without complete blockade, reducing toxicity risk.
- Exosome release is a physiological process; partial modulation is more physiologically compatible than complete inhibition.
- Concern: Broad exosome inhibition could impair beneficial immune signaling and intercellular communication. Careful dose-response studies are essential.

Recommendation: Prioritize Rab27A as the lead target; develop CSF exosomal tau (phospho-species) as the primary pharmacodynamic biomarker. Proceed to IND-enabling studies within 3–4 years.

Timeline: 5–7 years to Phase II-ready candidate. Cost estimate: $50–70M (biomarker standardization represents the primary investment).

---

Hypothesis 3: Tunneling Nanotubes (Glia-Neuron, Mid-Disease)

Revised Confidence: 0.56 | Disease Stage: Mid (Braak II–IV) | Regional Focus: Distributed

Druggability: ⚠️ High Risk

- M-Sec (TNFAIP2): Intracellular protein; not a classical druggable target. RNAi approaches are theoretically possible but face delivery challenges. No structural biology data available for rational drug design.
- Myo10 (Myosin X): Motor protein involved in filopodia and TNT formation. Larger target with less tractable pharmacology. Limited expression pattern (neurons and some glia) is theoretically an advantage.
- RhoA/ROCK1: Well-druggable pathway with FDA-approved inhibitors (fasudil, Y-27632). However, ROCK inhibition has profound effects on vascular smooth muscle, cytoskeleton, and blood pressure—clinical use would require careful CNS-selective delivery.
- Prion protein (PRNP) at TNT contacts: PRNP is druggable (antibodies exist; small molecules in development). However, PRNP has multiple functions beyond TNT-mediated tau transfer; complete blockade could have unexpected consequences.

Druggability verdict: Lowest tractability of the six hypotheses. M-Sec and Myo10 lack structural anchor points for drug design. ROCK inhibitors are viable but lack specificity for TNTs. Not recommended as a primary therapeutic program.

Biomarkers and Model Systems: ⚠️ Significant Gaps

- Biomarkers: No clinical biomarker for TNT density or activity exists. TNTs are not accessible to blood or CSF measurement. Functional readouts require imaging, which limits clinical translation.
- Model systems: 2D co-culture systems overstate TNT density compared to authentic tissue. Brain organoids show more realistic TNT formation but are not high-throughput. Correlative cryo-EM/ET (proposed validation) is low-throughput and not scalable for drug screening.
- Gap: There is no high-throughput assay suitable for compound screening against TNT-dependent tau transfer. This represents a fundamental barrier to drug discovery.

Clinical Development Constraints: ⚠️ Major

- TNTs are not clinically targetable: Even if the mechanism is validated, there is no feasible path to measuring TNT activity in human brain or monitoring target engagement in clinical trials.
- Regional specificity: The hypothesis claims TNTs are "critical in mid-disease progression" but does not define specific anatomical regions where TNTs predominate, limiting patient selection strategies.
- Endpoint problem: Without a biomarker for TNT function, clinical endpoints would rely on downstream tau PET signal—indirect and noisy.

Safety: ⚠️ Unknown

- TNT formation may be essential for normal CNS repair and intercellular communication. Adult CNS plasticity and regeneration may depend on TNT-like structures.
- ROCK inhibitors have established safety profiles but are not CNS-approved drugs in the US (fasudil is approved in Japan for pulmonary hypertension).

Recommendation: Deprioritize as a primary therapeutic target. Basic research funding should continue (validation experiments), but do not initiate drug discovery programs. Revisit if M-Sec structural biology becomes available or if specific TNT biomarkers emerge.

Timeline: Not feasible to advance to clinical development within a 10-year window given current tools. Cost estimate: Would require foundational biomarker work before any development cost estimate is meaningful.

---

Hypothesis 4: Retromer Dysfunction (Early Endosomes, All Regions)

Revised Confidence: 0.67 | Disease Stage: Early-to-Mid (All stages) | Regional Focus: Pan-cortical

Druggability: ✅ Highly Tractable

- VPS35: The most critical node. VPS35 is a protein-protein interaction hub with multiple interfaces amenable to small-molecule modulation. The VPS35 D620N mutation (linked to familial PD) provides a validated genetic anchor for therapeutic relevance.
- R33 and compound series: R33 (retromer activator) has been reported to reduce tau spreading in P301S mice. This is the strongest therapeutic candidate emerging from this set of hypotheses. The compound series has been optimized by academic groups and shows reasonable structure-activity relationships.
- SNX3, WASH complex (STRIPAK): Additional modulatory targets with reasonable tractability.
- VPS26A/VPS26B: Less druggable as a direct target (beta-propeller structure); better as a downstream outcome measure.

Druggability verdict: Retromer activation is the most pharmacologically tractable mechanism among all six hypotheses. Small-molecule activators are feasible, and the R33 compound series provides a starting point. This is the most investment-ready hypothesis from a drug discovery standpoint.

Concern: The skeptic correctly notes that VPS35 D620N is a Parkinson's mutation, not an AD mutation. This requires careful mechanistic bridge-building—either the retromer dysfunction is a convergent pathway across neurodegenerative diseases (making AD therapeutic relevance plausible), or the tau-specific effects of VPS35 manipulation are mechanistically distinct from the PD-linked D620N pathway.

Biomarkers and Model Systems: ✅ Strong

- Biomarkers: Early endosome enlargement is measurable by MRI (relatively established), super-resolution microscopy in patient-derived neurons, and CSF biomarkers (endosomal markers such as Rab5 and LAMP1 in extracellular vesicles). VPS35 expression levels in CSF are theoretically measurable. This provides multiple pharmacodynamic readout options.
- Model systems: VPS35flox/flox × CamKII-Cre and GFAP-Cre crosses (as proposed) are achievable within 12–18 months.

📊 Synthesizer — Round 4

3,985.0 tokens

```json
{
"ranked_hypotheses": [
{
"title": "VPS35 retromer activation prevents endosomal tau templating across all brain regions and disease stages",
"description": "Retromer dysfunction creates a permissive early endosome compartment where low pH and molecular crowding promote tau fibrillization, amplifying propagation regardless of the primary release mechanism (synaptic, exosomal, or TNT-mediated). The R33 small-molecule activator series provides a pharmacologically tractable entry point that is investment-ready. This mechanism operates pan-cortically and across disease stages, making it the most broadly applicable therapeutic target.",
"target_gene": "VPS35",
"dimension_scores": {
"evidence_strength": 0.67,
"novelty": 0.65,
"feasibility": 0.80,
"therapeutic_potential": 0.80,
"mechanistic_plausibility": 0.75,
"druggability": 0.80,
"safety_profile": 0.70,
"competitive_landscape": 0.70,
"data_availability": 0.75,
"reproducibility": 0.75
},
"composite_score": 0.74,
"evidence_for": [
{"claim": "VPS35 knockdown causes tau accumulation in early endosomes", "pmid": "35905925"},
{"claim": "Small molecule retromer activator R33 reduces tau spreading in P301S mice", "pmid": "37426941"},
{"claim": "VPS35 expression inversely correlates with tau burden in AD postmortem brain", "pmid": "37141857"},
{"claim": "Retromer deficiency increases tau propagation in human neuronal cultures", "pmid": "37354017"}
],
"evidence_against": [
{"claim": "VPS35 D620N mutation is linked to Parkinson's disease, not AD; mechanistic translatability unclear", "pmid": "N/A"},
{"claim": "Retromer dysfunction observed in aging brains without tau pathology, suggesting it may be consequence rather than cause", "pmid": "N/A"}
]
},
{
"title": "Rab27A/B-mediated exosomal tau secretion from microglia drives frontal cortex propagation at Braak III-VI",
"description": "Exosomal propagation becomes predominant in frontal regions during later Braak stages through ESCRT-dependent mechanisms. CD9/CD81 tetraspanin-enriched exosomes carry specific phospho-tau conformers that correlate with Braak stage. Rab27A/B GTPase represents the most selective therapeutic target within this pathway. CNS-derived exosomes isolatable from CSF provide a directly measurable pharmacodynamic biomarker, enabling streamlined Phase I/II trial design.",
"target_gene": "RAB27A",
"dimension_scores": {
"evidence_strength": 0.66,
"novelty": 0.70,
"feasibility": 0.70,
"therapeutic_potential": 0.70,
"mechanistic_plausibility": 0.72,
"druggability": 0.65,
"safety_profile": 0.70,
"competitive_landscape": 0.65,
"data_availability": 0.75,
"reproducibility": 0.70
},
"composite_score": 0.69,
"evidence_for": [
{"claim": "Exosome inhibition (GW4869) reduces microglial tau spread in vivo", "pmid": "26297806"},
{"claim": "Exosomal tau correlates with Braak stage; unique phosphorylation signature identified", "pmid": "33177547"},
{"claim": "CD9-positive exosomes from AD patient CSF induce tau aggregation in recipient cells", "pmid": "33509923"},
{"claim": "Syntenin-ALIX pathway preferentially packages phosphorylated tau into exosomes", "pmid": "33980767"}
],
"evidence_against": [
{"claim": "CD9/CD63+ vesicles may contaminate from plasma membrane vesicles, not true exosomes", "pmid": "N/A"},
{"claim": "Exosomal tau may represent clearance mechanism rather than pathological propagation", "pmid": "N/A"}
]
},
{
"title": "Astrocyte LRP1-mediated tau uptake and APOE4-dependent secretion creates regional susceptibility gradients",
"description": "APOE4 genotype modulates astrocyte tau handling—accelerating degradation while paradoxically increasing seeding-competent fragment secretion. Astrocyte LRP1 deletion reduces tau burden by ~40% in hTau mice. Regional differences in astrocyte APOE and LRP1 expression create intrinsic vulnerability gradients across entorhinal cortex, hippocampus, and frontal cortex. LRP1 antibody approaches are viable, though APOE4-specific window requires precise patient stratification.",
"target_gene": "LRP1",
"dimension_scores": {
"evidence_strength": 0.63,
"novelty": 0.70,
"feasibility": 0.55,
"therapeutic_potential": 0.60,
"mechanistic_plausibility": 0.65,
"druggability": 0.55,
"safety_profile": 0.60,
"competitive_landscape": 0.65,
"data_availability": 0.60,
"reproducibility": 0.60
},
"composite_score": 0.61,
"evidence_for": [
{"claim": "APOE4 astrocytes show increased tau propagation vs. APOE3 in human iPSC models", "pmid": "38127599"},
{"claim": "Astrocyte-specific LRP1 deletion reduces tau burden by ~40% in hTau mice", "pmid": "38657031"},
{"claim": "Astrocytes mediate ~30% of total tau clearance in brain; APOE4 reduces efficiency", "pmid": "32084337"}
],
"evidence_against": [
{"claim": "Internal contradiction: accelerated degradation should reduce seeding material, not increase it", "pmid": "N/A"},
{"claim": "\"Susceptibility windows\" lacks quantitative framework or testable predictions", "pmid": "N/A"}
]
},
{
"title": "LRP1-mediated synaptic uptake drives early entorhinal-hippocampal tau propagation (Braak I-II)",
"description": "Activity-dependent synaptic release at presynaptic terminals drives initial entorhinal-hippocampal propagation via VAMP2/synaptobrevin machinery, with post-synaptic uptake through LRP1 and Syndecan-3. NMDAR/CaMKII signaling modulates release. Critically, VAMP2 and STXBP1 are NOT viable targets due to essential synaptic function—LRP1 is the only druggable node within this mechanism. Early-stage intervention window is challenging for clinical development given typical AD diagnosis timing.",
"target_gene": "LRP1",
"dimension_scores": {
"evidence_strength": 0.62,
"novelty": 0.65,
"feasibility": 0.55,
"therapeutic_potential": 0.50,
"mechanistic_plausibility": 0.68,
"druggability": 0.40,
"safety_profile": 0.35,
"competitive_landscape": 0.60,
"data_availability": 0.70,
"reproducibility": 0.65
},
"composite_score": 0.57,
"evidence_for": [
{"claim": "Activity-dependent tau release from synapses demonstrated in primary hippocampal neurons", "pmid": "29162631"},
{"claim": "Trans-synaptic spread of tau in Thy1-hTau mice requiring intact synapses", "pmid": "22496542"},
{"claim": "LRP1 knockdown reduces neuronal tau uptake by ~80%", "pmid": "30872492"},
{"claim": "Syndecan-3 mediates tau internalization and hippocampal spread", "pmid": "32084337"}
],
"evidence_against": [
{"claim": "VAMP2/synaptobrevin is required for ALL synaptic vesicle fusion; targeting causes catastrophic neurotransmission disruption", "pmid": "N/A"},
{"claim": "TTX block of neuronal activity shows incomplete inhibition of tau spread, indicating redundant pathways", "pmid": "N/A"}
]
},
{
"title": "M-Sec/TNTA2-mediated tunneling nanotube formation drives glia-neuron tau propagation in mid-stages",
"description": "TNTs (20-150 nm actin-based membrane bridges) enable direct astrocyte-neuron and microglia-neuron tau transfer without extracellular release, predominating when extracellular burden is high but before extensive neuronal loss. M-Sec (TNFAIP2) and Myo10 orchestrate TNT formation; PRNP facilitates transfer. Critical gaps: no clinical biomarker exists, no high-throughput screening assay is available, and physical plausibility of tau fibrils fitting in 20-150nm TNTs is questionable.",
"target_gene": "TNFAIP2",
"dimension_scores": {
"evidence_strength": 0.56,
"novelty": 0.80,
"feasibility": 0.35,
"therapeutic_potential": 0.40,
"mechanistic_plausibility": 0.60,
"druggability": 0.30,
"safety_profile": 0.45,
"competitive_landscape": 0.75,
"data_availability": 0.45,
"reproducibility": 0.50
},
"composite_score": 0.52,
"evidence_for": [
{"claim": "TNTs mediate tau transfer from astrocytes to neurons; blocking M-Sec reduces transfer by ~70%", "pmid": "33846639"},
{"claim": "Myo10 knockdown prevents TNT formation and reduces tau spread in co-culture", "pmid": "34949727"},
{"claim": "Prion protein at TNT contacts facilitates tau oligomer transfer bidirectionally", "pmid": "37449476"}
],
"evidence_against": [
{"claim": "Tau oligomers/fibrils (20-50nm) may not physically fit within 20-150nm diameter TNTs", "pmid": "N/A"},
{"claim": "No clinical biomarker exists for TNT density or activity; not targetable in human trials", "pmid": "N/A"}
]
},
{
"title": "P2Y6R activation by UDP from damaged neurons drives microglial phagocytosis and exosomal re-secretion in mid-to-late disease",
"description": "Neuronal damage exposes phosphatidylserine and releases UDP, activating microglial P2Y6R and triggering phagocytosis of tau-positive debris. Internalized tau is processed through endo-lysosomal system and released in exosomes via RAB27A/Synaptotagmin-7, creating a feed-forward propagation loop. TREM2 normally inhibits this pathway; TREM2 deficiency accelerates spread. Evidence is truncated and mechanism has too many sequential dependencies for robust therapeutic development.",
"target_gene": "P2RY6",
"dimension_scores": {
"evidence_strength": 0.58,
"novelty": 0.65,
"feasibility": 0.45,
"therapeutic_potential": 0.50,
"mechanistic_plausibility": 0.60,
"druggability": 0.50,
"safety_profile": 0.55,
"competitive_landscape": 0.70,
"data_availability": 0.45,
"reproducibility": 0.50
},
"composite_score": 0.54,
"evidence_for": [
{"claim": "P2Y6R knockout reduces tau propagation and microglial tau exosome release in P301S mice by ~60%", "pmid": "35705897"},
{"claim": "TREM2 deficiency increases microglial tau exosome secretion; TREM2 agonism reduces propagation", "pmid": "36951963"}
],
"evidence_against": [
{"claim": "Supporting evidence section is truncated; hypothesis underdeveloped with incomplete citations", "pmid": "N/A"},
{"claim": "UDP release as damage signal occurs in stroke, trauma, and other conditions—not specific to AD", "pmid": "N/A"}
]
}
],
"knowledge_edges": [
{"source_id": "hypothesis_1", "source_type": "hypothesis", "target_id": "LRP1", "target_type": "gene", "relation": "postsynaptic receptor mediates tau uptake"},
{"source_id": "hypothesis_1", "source_type": "hypothesis", "target_id": "VAMP2", "target_type": "gene", "relation": "NOT VIABLE - essential for all synaptic transmission"},
{"source_id": "hypothesis_1", "source_type": "hypothesis", "target_id": "STXBP1", "target_type": "gene", "relation": "NOT VIABLE - Munc18-1 mutations cause severe developmental encephalopathy"},
{"source_id": "hypothesis_2", "source_type": "hypothesis", "target_id": "RAB27A", "target_type": "gene", "relation": "GTPase controlling exosome release; viable therapeutic target"},
{"source_id": "hypothesis_2", "source_type": "hypothesis", "target_id": "CD9", "target_type": "gene", "relation": "tetraspanin for exosome identification; antibody approaches feasible"},
{"source_id": "hypothesis_2", "source_type": "hypothesis", "target_id": "CHMP2B", "target_type": "gene", "relation": "NOT VIABLE - ESCRT machinery essential; inhibition causes toxicity"},
{"source_id": "hypothesis_3", "source_type": "hypothesis", "target_id": "TNFAIP2", "target_type": "gene", "relation": "M-Sec orchestrator of TNT formation; NOT druggable (intracellular protein)"},
{"source_id": "hypothesis_3", "source_type": "hypothesis", "target_id": "PRNP", "target_type": "gene", "relation": "facilitates tau transfer at TNT contacts; antibody approaches viable but pleiotropic"},
{"source_id": "hypothesis_4", "source_type": "hypothesis", "target_id": "VPS35", "target_type": "gene", "relation": "PRIORITY TARGET - retromer core component; R33 activator series established"},
{"source_id": "hypothesis_5", "source_type": "hypothesis", "target_id": "LRP1", "target_type": "gene", "relation": "astrocyte uptake receptor; antibody development tractable"},
{"source_id": "hypothesis_5", "source_type": "hypothesis", "target_id": "APOE", "target_type": "gene", "relation": "APOE4 genotype creates vulnerability; patient stratification target"},
{"source_id": "hypothesis_6", "source_type": "hypothesis", "target_id": "P2RY6", "target_type": "gene", "relation": "GPCR - druggable but mechanism has too many sequential dependencies"},
{"source_id": "hypothesis_6", "source_type": "hypothesis", "target_id": "TREM2", "target_type": "gene", "relation": "inhibits microglial tau exosome release; TREM2 agonism is competing approach"},
{"source_id": "hypothesis_1", "source_type": "hypothesis", "target_id": "hypothesis_4", "target_type": "hypothesis", "relation": "convergence at LRP1; retromer dysfunction may modulate synaptic uptake efficiency"},
{"source_id": "hypothesis_2", "source_type": "hypothesis", "target_id": "hypothesis_6", "target_type": "hypothesis", "relation": "both involve exosomal release; P2Y6R pathway may feed into exosome-dependent propagation"},
{"source_id": "hypothesis_5", "source_type": "hypothesis", "target_id": "hypothesis_1", "target_type": "hypothesis", "relation": "LRP1 as shared node; astrocyte LRP1 and synaptic LRP1 may have distinct therapeutic profiles"}
],
"synthesis_summary": "The debate reveals that all six tau propagation mechanisms likely operate in parallel rather than in hierarchical sequence, fundamentally shifting the therapeutic strategy from selecting a single dominant mechanism to identifying the most pharmacologically tractable intervention point. The highest-priority hypothesis is retromer dysfunction (composite score 0.74), which operates as a pan-cortical amplifier across all disease stages and disease regions—the R33 small-molecule activator series provides an investment-ready starting point with demonstrated efficacy in P301S mice. Exosomal propagation (score 0.69) ranks second with the strongest biomarker infrastructure (CSF-derived CNS exosomes with Braak-stage-correlated phospho-tau signatures) and a viable target in Rab27A/B; this hypothesis is particularly suitable for later-stage patient populations identifiable by established tau PET positivity. A critical finding is that VAMP2, STXBP1 (Munc18-1), and ESCRT machinery (CHMP2B, VPS4) must be excluded from therapeutic targeting due to essential cellular functions—LRP1 emerges as a shared viable node across hypotheses 1 and 5. Tunneling nanotubes (score 0.52) and P2Y6R-mediated microglial loops (score 0.54) are deprioritized for clinical development due to absence of clinical biomarkers and incomplete evidence bases respectively; basic research validation should continue but drug discovery programs should not be initiated. The most important near-term investments are: (1) standardizing CNS exosome isolation and phospho-tau MS profiling for multicenter clinical trials, (2) completing the mechanistic bridge between VPS35 D620N (PD-linked) and AD-type tau pathology to validate retromer as an AD target, and (3) developing LRP1 antibody programs that can be selectively directed at synaptic versus astrocytic compartments."
}
```